Commercial tests that detect Nuclear Matrix Protein 22 (NMP22) [6] or Bladder Tumor Antigen (BTA) [7] are FDA-approved tests for BCa diagnosis, but these single-marker assays lack the specificity of voided urine cytology [8]. Here, NUMA1 is linked to neoplasm.